18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation

Citer cette référence
IMPERIALE, A., RUST, E., GABRIEL, S., DETOUR, J., GOICHOT, Bernard, DUCLOS, B., KURTZ, J. E., BACHELLIER, P., NAMER, I. J. et TAIEB, D., 2014. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. The Journal of Nuclear Medicine [en ligne]. 2014. Vol. 55, n° 3pp. 367-372. [Consultésans date]. DOI 10.2967/jnumed.113.126896. Consulté de : http://www.ncbi.nlm.nih.gov/pubmed/24343986
Pas de texte intégral
Auteurs A Imperiale
E Rust
S Gabriel
J Detour
Bernard Goichot
B Duclos
J Kurtz
P Bachellier
I Namer
D Taieb
Unité de recherche du site Laboratoire de neurobiologie et pharmacologie cardiovasculaire - LNPCV – EA7296
Langue

en
Volume

55
Numéro

3
Page de début

367
Page de fin

372
Date de première publication

2014
ISSN

1535-5667
Titre de la source (revue, livre…)

The Journal of Nuclear Medicine
Résumé

This work was performed to evaluate the performance of (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET/CT in detecting primary neuroendocrine tumors (NETs) occult on morphologic and functional imaging, in relation to tumor origin and Show moreThis work was performed to evaluate the performance of (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET/CT in detecting primary neuroendocrine tumors (NETs) occult on morphologic and functional imaging, in relation to tumor origin and differentiation. METHODS: A retrospective study of NET patients who were investigated with (18)F-FDOPA PET/CT imaging in 2 academic endocrine tumor centers was conducted. Only patients with negative conventional and somatostatin receptor scintigraphy (SRS) results were studied. RESULTS: Twenty-seven patients were evaluated with (18)F-FDOPA PET/CT, 23 at their initial staging and 4 during their follow-up. The primary occult NET was localized by (18)F-FDOPA PET/CT in 12 patients (overall sensitivity, 44%; 52% in patients evaluated at initial diagnosis), leading to tumor resection in all cases. The primary tumors were distributed and graded as follows: 1 duodenum G2 lesion, 7 ileum G2 lesions, 2 terminal ileum G1 lesions, 1 pancreas G2 lesion, and 1 gallbladder G3 lesion. Patients with positive (18)F-FDOPA PET/CT results had higher values of serum chromogranin A (100% vs. 20%, P = 0.0003), serotonin, or urinary 5-hydroxyindolacetic acid (83% vs. 20%, P = 0.003). Two false-negative results were related to poorly differentiated duodenal and prostatic NETs (G3). (18)F-FDOPA PET/CT showed more metastatic anatomic regions than SRS in 17 patients. CONCLUSION: (18)F-FDOPA PET appears to be a sensitive functional imaging tool for the detection of primary NETs occult on SRS, especially tumors with a well-differentiated pattern and serotonin secretion. Show less
DOI 10.2967/jnumed.113.126896
Éditeur

Society of Nuclear Medicine
URL éditeur http://www.ncbi.nlm.nih.gov/pubmed/24343986
Type de publication

journal article
Type de publication

ACL
Fonction

ctb
aut
URL https://univoak.eu/islandora/object/islandora:57638